US5559094A
(en)
*
|
1994-08-02 |
1996-09-24 |
Eli Lilly And Company |
AspB1 insulin analogs
|
US6251856B1
(en)
|
1995-03-17 |
2001-06-26 |
Novo Nordisk A/S |
Insulin derivatives
|
KR19980703039A
(en)
*
|
1995-03-17 |
1998-09-05 |
켈스버그 라아스 |
Insulin derivatives
|
DE19726167B4
(en)
|
1997-06-20 |
2008-01-24 |
Sanofi-Aventis Deutschland Gmbh |
Insulin, process for its preparation and pharmaceutical preparation containing it
|
US7638618B2
(en)
|
2001-02-20 |
2009-12-29 |
Sanofi-Aventis Deutschland Gmbh |
Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
|
US7202059B2
(en)
|
2001-02-20 |
2007-04-10 |
Sanofi-Aventis Deutschland Gmbh |
Fusion proteins capable of being secreted into a fermentation medium
|
DE10114178A1
(en)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinc-free and low-zinc insulin preparations with improved stability
|
DE10227232A1
(en)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Sour insulin preparations with improved stability
|
ATE550041T1
(en)
|
2004-01-21 |
2012-04-15 |
Novo Nordisk Healthcare Ag |
TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
|
CN101573133B
(en)
|
2006-07-31 |
2014-08-27 |
诺沃-诺迪斯克有限公司 |
PEGylated, extended insulins
|
EP2074141B1
(en)
|
2006-09-22 |
2016-08-10 |
Novo Nordisk A/S |
Protease resistant insulin analogues
|
CN101674812B
(en)
|
2007-04-30 |
2013-12-11 |
诺沃-诺迪斯克有限公司 |
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
|
CN102007143B
(en)
|
2008-01-09 |
2015-08-26 |
塞诺菲-安万特德国有限公司 |
There is the novel insulin derivates of super delayed aging feature
|
JP5762001B2
(en)
|
2008-03-14 |
2015-08-12 |
ノボ・ノルデイスク・エー/エス |
Protease stabilized insulin analogue
|
WO2009115469A1
(en)
|
2008-03-18 |
2009-09-24 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
DE102008053048A1
(en)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
|
RS56632B1
(en)
|
2008-10-17 |
2018-03-30 |
Sanofi Aventis Deutschland |
Combination of an insulin and a glp-1 agonist
|
DE102009038210A1
(en)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Medicament, useful e.g. for treating diabetes, controlling fasting, postprandial or postabsorptive blood glucose concentration in diabetic patients and improving glucose tolerance, comprises insulin and glucagon-like peptide-1 agonist
|
DE102008051834A1
(en)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Drug, useful e.g. for treating diabetes, preferably type-I or II and for controlling fasting, postprandial and/or postabsorptive plasma glucose concentration, comprises insulin and glucagon-like peptide-1 agonist
|
DE102008064270A1
(en)
*
|
2008-12-20 |
2010-07-01 |
Voith Patent Gmbh |
Flotation method for removing contaminants from aqueous fibrous material suspension by gas bubbles, involves supplying stream of fibrous material suspension along interference body after supplying stream of gas
|
WO2011003820A1
(en)
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Heat- and vibration-stable insulin preparations
|
EP2451471A1
(en)
|
2009-07-06 |
2012-05-16 |
Sanofi-Aventis Deutschland GmbH |
Slow-acting insulin preparations
|
KR101852328B1
(en)
|
2009-07-06 |
2018-04-26 |
사노피-아벤티스 도이칠란트 게엠베하 |
Aqueous insulin preparations containing methionine
|
AU2010277559B2
(en)
|
2009-07-31 |
2016-08-11 |
Sanofi-Aventis Deutschland Gmbh |
Prodrugs comprising an insulin linker conjugate
|
UA108475C2
(en)
|
2009-07-31 |
2015-05-12 |
Санофі-Авентіс Дойчланд Гмбх |
Long-acting insulin composition
|
ES2855146T3
(en)
|
2009-11-13 |
2021-09-23 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
|
PT3345593T
(en)
|
2009-11-13 |
2023-11-27 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising despro36exendin-4(1-39)-lys6-nh2 and methionine
|
AU2011269000C1
(en)
|
2010-06-23 |
2015-10-08 |
Novo Nordisk A/S |
Insulin derivatives containing additional disulfide bonds
|
CN102947331B
(en)
*
|
2010-06-23 |
2016-08-03 |
诺沃—诺迪斯克有限公司 |
Comprise the insulin analog of extra disulfide bond
|
JP6013330B2
(en)
|
2010-06-23 |
2016-10-25 |
ノヴォ ノルディスク アー/エス |
Human insulin containing additional disulfide bonds
|
HUE031181T2
(en)
|
2010-08-30 |
2017-06-28 |
Sanofi Aventis Deutschland |
Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
CN103533952B
(en)
|
2011-03-15 |
2017-02-15 |
诺沃—诺迪斯克有限公司 |
Human insulin analogues and derivatives comprising cysteine substitutions
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
CN103917241A
(en)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
|
AR087744A1
(en)
|
2011-09-01 |
2014-04-16 |
Sanofi Aventis Deutschland |
PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
|
US9481721B2
(en)
|
2012-04-11 |
2016-11-01 |
Novo Nordisk A/S |
Insulin formulations
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
DK2854841T3
(en)
|
2012-06-04 |
2017-05-22 |
Diamedica Inc |
Kallikrein-1-glycosylation isoforms of human tissue
|
CA2889165A1
(en)
|
2012-12-19 |
2014-06-26 |
Wockhardt Limited |
A stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
JP2016505601A
(en)
|
2012-12-26 |
2016-02-25 |
ウォックハート リミテッド |
Pharmaceutical composition
|
TWI780236B
(en)
|
2013-02-04 |
2022-10-11 |
法商賽諾菲公司 |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
AU2014326181A1
(en)
|
2013-09-30 |
2016-03-17 |
Wockhardt Limited |
Pharmaceutical composition
|
HUE036702T2
(en)
|
2013-10-07 |
2018-07-30 |
Novo Nordisk As |
Novel derivative of an insulin analogue
|
EP3091964A1
(en)
|
2014-01-09 |
2016-11-16 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
US9839692B2
(en)
|
2014-01-09 |
2017-12-12 |
Sanofi |
Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
BR112016013832A2
(en)
|
2014-01-09 |
2017-08-08 |
Sanofi Sa |
USE OF INSULIN ANALOG AND/OR DERIVATIVE, PHARMACEUTICAL FORMULATION AND PROCESS FOR THE PREPARATION OF THE SAME, KIT AND MEDICAL DEVICE
|
WO2016001862A1
(en)
|
2014-07-04 |
2016-01-07 |
Wockhardt Limited |
Extended release formulations of insulins
|
JP6970615B2
(en)
|
2014-12-12 |
2021-11-24 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Insulin glargine / lixisenatide fixed ratio prescription
|
TWI748945B
(en)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
Treatment type 2 diabetes mellitus patients
|
TW201705975A
(en)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
Treatment of type 2 diabetes mellitus patients
|
CN115154591B
(en)
|
2016-12-16 |
2023-04-14 |
诺和诺德股份有限公司 |
Pharmaceutical composition containing insulin
|
EP3592377A4
(en)
|
2017-03-09 |
2021-02-17 |
Diamedica Inc. |
Dosage forms of tissue kallikrein 1
|
TW201917134A
(en)
|
2017-08-17 |
2019-05-01 |
丹麥商諾佛 儂迪克股份有限公司 |
Novel acylated insulin analogues and uses thereof
|